Oni

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oni

What is Oni? Dual-Action Topical Medicine

The medicinal entity known as Oni is a synthetic, fixed-dose combination product designed for topical administration to the skin. It is classified as a potent corticosteroid and antifungal combination, a specialized preparation used in dermatology to address conditions where both inflammation and fungal infection are present. This dual-action approach is clinically recognized for providing comprehensive relief in mixed dermatological conditions.


Property Description
Active Ingredients Betamethasone Dipropionate, Clotrimazole
Form Cream or Ointment
Pharmacological Class Topical Corticosteroid and Antifungal Combination
Common Use Management of inflammatory and fungal skin conditions
Origin Synthetic Compounds

What Type of Medicine is Oni and Its Classification?

Oni is classified as a combination drug blending a glucocorticoid with a broad-spectrum antifungal agent. This places it within the drug class of Topical Steroids with Anti-infectives. The medication is a synthetic compound, as both the corticosteroid (Betamethasone Dipropionate) and the antifungal (Clotrimazole) are chemically manufactured entities. Its administration route is strictly topical, meaning it is applied directly to the skin surface, typically under a prescription-only (Rx) status.

Active Ingredients in Oni: Betamethasone Dipropionate and Clotrimazole

The formulation of Oni contains two principal active ingredients: Betamethasone Dipropionate and Clotrimazole. Betamethasone Dipropionate is recognized as a highly effective corticosteroid that manages the body's inflammatory response by inducing local vasoconstriction, which helps reduce redness and swelling. Clotrimazole is an imidazole antifungal, a class of agents that inhibit the growth of and eradicate common fungi and yeasts. The combination of these two agents provides a synergistic effect, resulting in more efficient symptomatic management than the antifungal alone.

General Purpose of the Dual-Action Formula

The general therapeutic purpose of Oni’s dual-action formula is to provide rapid symptomatic relief while simultaneously treating the pathogen. The combination leverages the strong anti-inflammatory action of Betamethasone Dipropionate to quickly reduce associated swelling and antipruritic effect (itching). Concurrently, the fungicidal action of Clotrimazole targets and eliminates the infectious organism. The primary benefit is addressing two factors of a dermatological issue at once.

Regulatory References

  1. Topical Antifungal Combinations | NIH DailyMed

What side effects are possible with Oni?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety restrictions for amlodipine, as categorized and reported by government regulatory authorities.

Frequency and Common Adverse Reactions

The safety profile distinguishes between common side effects and rare but serious events. The most frequently documented reactions include those with an incidence greater than 1.0% in clinical trials:

  • Edema: Swelling, typically of the hands, feet, ankles, or lower legs (often dose-related).
  • Headache
  • Fatigue or excessive tiredness
  • Dizziness (often dose-related)
  • Flushing (hot or warm feeling in the face, often dose-related)
  • Nausea
  • Palpitations

Side effects are categorized by the affected System-Organ-Class (SOC), including the Cardiovascular, Central and Peripheral Nervous System, and Gastrointestinal systems.

Serious Adverse Reactions and Safety Cautions

Certain adverse events are documented as potentially serious and require specific caution:

  • Worsening Angina or Acute Myocardial Infarction: This is a documented risk, particularly upon initiating or increasing the dose in patients with severe obstructive coronary artery disease.
  • Symptomatic Hypotension: A significant drop in blood pressure, which may occur, particularly in patients with severe aortic stenosis.
  • Allergic Reactions: Rare but documented reactions, including angioedema (swelling of the face, lips, tongue, or throat).

Population-Specific Considerations

The following safety considerations are noted for specific patient groups in regulatory documents:

  • Hepatic Impairment: Caution is advised, and slower dose adjustment may be necessary due to the drug’s prolonged half-life in patients with liver disease.
  • Geriatric Patients: A lower initial dose is typically advised.

Safety-Related Restrictions

Safety documents specify restrictions, including a contraindication for individuals with known hypersensitivity (e.g., angioedema) to amlodipine or other calcium channel blockers of the dihydropyridine class. The use in severe aortic stenosis and severe obstructive coronary artery disease requires particular caution.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Oni is a medical emergency that requires immediate professional attention.

Documented Overdose Presentations

Official regulatory information describes overdose primarily by the associated signs, symptoms, and laboratory findings. These may include complications such as organ toxicity or delayed acidosis, which can be life-threatening. The clinical picture is often defined by the specific physiological systems affected by the drug.

Factors relating to severity include the exposure level or single dose amount that is ordinarily associated with symptoms or is likely to be life-threatening.

Emergency Response

Always call for emergency medical help immediately if an overdose is suspected. Procedural instructions for managing an overdose are required by regulatory authorities to guide healthcare professionals in stabilization and treatment. These official statements cover specific measures for support of vital functions, general overdose treatment procedures, and the use of antidotes if available.

Treatment may also involve methods to increase the elimination of the drug from the body, such as dialysis, depending on the drug's properties and the specific clinical needs of the patient.

Regulatory documents emphasize that the overdose section must be based on human data, or appropriate animal and in vitro data if human information is unavailable. This information is intended strictly for professional use to facilitate the timely, appropriate response to acute overexposure.

Therapeutic Uses of Oni

Oni is commonly used in clinical settings that involve acute or unstable symptom patterns arising from inflammatory fungal infections.


Acute Management of Inflammatory Fungal Infections

This medication is applied in situations where patients experience symptomatic discomfort from specific superficial fungal infections, such as tinea pedis (athlete’s foot), tinea cruris (jock itch), and tinea corporis (ringworm), when these conditions are also characterized by periods of heightened inflammatory symptoms. It is used in situations involving certain distressing symptoms, assisting with the therapeutic goal of resolving the fungal infection alongside support for short-term symptomatic assistance during the phase of heightened distress.

“It is commonly used across conditions presenting with acute episodes where inflammation and fungal presence benefit from simultaneous management.”


Relief of Intense Itching and Discomfort

Oni is considered relevant for easing symptoms related to inflammatory or irritative states, such as intense pruritus (itching), erythema (redness), and localized swelling. The combination helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms and assisting with maintaining functional stability when discomfort interferes with routine activities.

Relevant Fact: Relief for Symptomatic Itching

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Oni

The eligibility profile for Oni (Betamethasone Dipropionate/Clotrimazole) is strictly defined by regulatory documents, distinguishing between populations allowed to use the medicine and those who are formally contraindicated.


Regulatory Eligibility Constraints

Classification Population/Condition Restriction Basis
Contraindicated Patients with known hypersensitivity to any component. Absolute Exclusion
Contraindicated Non-fungal skin infections, including viral lesions, rosacea, or perioral dermatitis. Disease-Specific Exclusion
Not Recommended Pediatric patients under 17 years of age. Systemic Absorption Risk
Conditional Use Pregnancy and Lactation. Risk-Benefit Evaluation

Official Eligibility Statements

Adults are the standard eligible population for this topical combination. Use is absolutely contraindicated for patients with a known allergy to the active ingredients or other imidazole antifungals. The medicine must not be used for specific non-fungal conditions such as viral lesions, tuberculosis of the skin, or rosacea, as defined in official labeling. Use in children under the minimum age is generally contraindicated due to the high risk of systemic toxicity. For patients who are pregnant or breastfeeding, use is restricted and only permitted if the potential benefit justifies the risk, according to regulatory guidance.

What should I know about interactions with other medicines?

The regulatory profile for Oni (Betamethasone Dipropionate/Clotrimazole) is defined by specific interaction patterns documented in authoritative government sources. No substances are explicitly listed as formally contraindicated combinations based on drug-drug interaction risk in the official prescribing information.

Additive Exposure Risk and Product Constraints

The most significant interaction involves additive exposure risk. Co-administration of other corticosteroid-containing products (topical or systemic) may result in an increase in total systemic glucocorticoid exposure due to an additive pharmacodynamic effect. This outcome increases the potential for systemic effects, such as Hypothalamic-Pituitary-Adrenal (HPA) axis suppression.

Interaction Type Interacting Product / Substance Official Constraint / Outcome
Pharmacodynamic Exposure Other Corticosteroid-containing products Increases total systemic glucocorticoid exposure due to additive effect.
Product Integrity Barrier Contraceptive Products (Condoms, Diaphragms) Active component Clotrimazole may cause damage to the material, resulting in product failure.

This potential for heightened systemic exposure is subject to population-specific interaction considerations. Pediatric patients are noted to be at an increased susceptibility to systemic toxicity from glucocorticoid exposure due to a higher surface area-to-body mass ratio. Furthermore, risk factors like liver failure are documented to potentially affect the clearance of absorbed Betamethasone, predisposing a patient to greater systemic effects. There are no mandatory dosing separation or timing requirements documented in the official regulatory label.

Mechanism of Action

Onasemnogene abeparvovec is a gene replacement therapy delivered via a non-replicating adeno-associated virus serotype 9 (AAV9) vector.

The AAV9 vector is specifically engineered to target and cross the blood-brain barrier, leading to selective accumulation within motor neurons and other tissues. The vector's payload is a functional human Survival Motor Neuron 1 (SMN1) transgene, accompanied by synthetic promoters. Following cellular entry, the AAV9 capsid translocates the SMN1 transgene to the motor neuron nucleus. The transgene establishes itself as a non-integrating episome and is immediately transcribed. This process results in the rapid and sustained production of the Survival Motor Neuron (SMN) protein within the targeted cells. The SMN protein is essential for the function and maintenance of motor neurons, playing a critical role in the biogenesis of the spliceosome, an intracellular ribonucleoprotein complex. System-level physiological consequences involve the restoration of SMN protein expression in motor neurons, which mitigates the molecular deficit responsible for the cellular dysfunction.

Dosage and Administration Information

How to Use Oni: Official Administration Guidelines

Oni (Betamethasone Dipropionate/Clotrimazole) is a dual-action topical medicine whose application is structured to ensure appropriate use and limit corticosteroid exposure. The information below details the standard administration protocols.


Route and Frequency

Oni is approved for topical application only to the skin surface; it must not be used orally or in the eyes. The standard dosing schedule requires the medicine to be applied twice daily, generally once in the morning and once in the evening.

Feature Official Instruction
Route of Administration Strictly Topical; External Use Only
Dosing Frequency Twice daily (Morning and Evening)

Application Technique and Restrictions

For proper use, a thin layer of the cream or ointment must be applied to cover the entire affected area and a small margin of surrounding skin. The preparation should be gently massaged into the skin until it disappears. Instructions indicate that the treated area must not be bandaged, covered, or wrapped (occluded) unless a healthcare professional advises otherwise.


Official Duration Limits

Oni is designated for short-term use. Treatment duration is explicitly limited to restrict the patient's exposure to the potent corticosteroid component. The general course of treatment should not exceed no more than two weeks. For tinea pedis (athlete’s foot), the course should not exceed four weeks.

If treatment for the fungal infection is required beyond the designated short-term limit, the combination product must be discontinued, and an appropriate preparation containing only the antifungal agent should be considered.

Population-Specific Use

For pediatric patients (12 years of age and older), use is also limited to the shortest duration consistent with a successful regimen, and treatment must not exceed two weeks.

Recent Clinical Evidence

Oni: Recent Clinical Evidence

Evidence for Use in Approved Condition 1 (Target Disease)

Research for Oni in its first approved condition includes several short-term Randomized Controlled Trials (RCTs). These studies were structured to compare the outcomes of patients receiving Oni against those receiving a placebo (an inactive treatment). The research was applied to adults diagnosed with moderate to severe symptoms in conditions marked by functional limitations and episodic manifestations. Researchers applied studies examining patient-reported experiences and specific clinical measurements to monitor symptom evolution over time. These short-term studies reported measurements of changes in the participants’ functional scale scores. Research highlights changes measured during the study period, and findings describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level. These study results reflect the specific conditions under which they were conducted.

Comparing Oni to Placebo and Standard Treatments

In the main trials, Oni was evaluated in research examining outcomes related to physical discomfort compared directly to a placebo. Additionally, some research examined Oni against other current standard treatments; these studies monitored and described differences in measured outcomes. These comparison studies contribute to the broader evidence landscape, providing insight into short-term changes. Findings may vary across studies, and comparative evidence for long-term outcomes is often lacking.

Evidence for Use in Approved Condition 2 (Secondary Target)

Oni was studied for its secondary approved condition in research that explored different scenarios. The available evidence includes intermediate-term non-inferiority trials. The study populations were mainly adults with conditions characterized by fluctuating or episodic manifestations.

Long-Term Studies and Follow-Up Data

While the main controlled trials typically evaluated outcomes over a few months, researchers also conducted long-term open-label extension studies (sometimes for up to 5 years). Long-term effects are not fully established, particularly concerning outcomes over many years, and certainty remains low.

What Is Still Uncertain About Oni's Research

Evidence quality varies across studies, and the follow-up durations were limited for long-term safety and outcome patterns. Comparative evidence is lacking for Oni versus other treatments over extended periods. For some specific groups, data are still emerging, and certainty remains low. Findings describe group patterns, not personal outcomes; evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Oni (FAQ)

Q: Is Oni the same as [common competitor drug name]?

Oni is a fixed-dose combination containing two active ingredients: a potent corticosteroid (Betamethasone Dipropionate) and an antifungal agent (Clotrimazole). This dual-action nature distinguishes it from products that contain only a single active ingredient.

Q: Will I feel better immediately after taking Oni, or is it a gradual change?

The corticosteroid component is designed to offer rapid symptomatic relief, such as reducing inflammation and itching, which may be noticeable soon after application. However, the full duration of treatment is determined by your healthcare provider, and the product labeling emphasizes the importance of completing the full course to effectively treat the underlying fungal infection.

Q: Can you drink alcohol while taking Oni, or is it risky?

Official drug labeling for topical Oni does not list alcohol as a specific substance to avoid or an interaction risk. Because it is a topical medication applied to the skin, the risk of systemic interaction is generally considered low, but official labeling provides no explicit guidance.

Q: Does Oni cause weight gain or weight loss?

Weight changes are not listed among the common side effects in the official prescribing information for Oni. Systemic effects, such as those related to the body's natural steroid balance, are possible with prolonged or excessive use of potent corticosteroids, which may sometimes involve weight changes.

Q: Do I need to worry about Oni interacting with common over-the-counter pain relievers?

The official prescribing information for Oni does not list specific interactions with common over-the-counter (OTC) pain relievers (like acetaminophen or NSAIDs). The primary interaction caution is against using it alongside other products containing corticosteroids due to the risk of increased systemic exposure.

Q: Can Oni be taken with supplements like vitamins or herbal remedies?

Official drug labeling does not provide specific guidance on taking Oni with supplements, vitamins, or herbal remedies. It is important for patients to inform their healthcare provider of all products, including supplements and herbal remedies, they are currently using.

Q: Does taking Oni increase sensitivity to the sun?

Official labeling does not list photosensitivity (increased sun sensitivity) as a common or serious adverse reaction for Oni. The labeling does not list photosensitivity as an adverse reaction.

Q: If I have a history of [mental health condition], can I still take Oni?

The official drug labeling does not list mental health conditions or psychiatric history as specific contraindications for the use of topical Oni. Contraindications are typically limited to known hypersensitivity (allergy) to the ingredients or use on specific non-fungal skin infections.

Q: Are the side effects of Oni permanent?

Adverse effects from the corticosteroid component, such as HPA axis suppression (a rare systemic effect), are generally considered reversible upon discontinuing the drug. Local side effects are generally expected to resolve upon discontinuation of the medication.

Q: Why do doctors prescribe Oni instead of other similar medications?

Doctors often prescribe Oni because its dual formulation provides both the anti-inflammatory action of a potent corticosteroid to quickly relieve symptoms (like itching) and the antifungal action of Clotrimazole to treat the underlying infection in one product.

Q: How long does Oni stay in your system after you stop taking it?

Although Oni is a topical product, a small amount of the corticosteroid component can be systemically absorbed. Recovery of normal body functions affected by this systemic exposure, such as HPA axis function, is generally considered prompt once the medication is stopped.

Q: What should I do if I miss a dose of Oni?

If a dose is missed, official product guidance addresses how to handle the situation, typically advising to apply it as soon as remembered unless it is almost time for the next dose.

Q: How quickly do side effects from Oni usually go away after stopping the drug?

Recovery from systemic effects (like HPA axis suppression) is typically prompt upon discontinuation of the topical corticosteroid. Local reactions that may have developed should also subside once treatment is stopped.

Q: Can men and women use Oni for the same conditions?

Yes, Oni is officially indicated for the treatment of specific inflammatory fungal skin infections (tinea pedis, tinea cruris, tinea corporis) and is used equally by both men and women for these approved conditions.

Q: Are there any specific activities or machinery to avoid when first starting Oni?

Official drug labeling does not contain any specific warnings or precautions about avoiding particular activities or operating machinery after applying topical Oni.

Q: Is it safe to drive after taking Oni?

Official drug labeling does not include any warnings or precautions regarding the effect of Oni on a patient's ability to drive, as it is a topical medicine.

Q: Can I take Oni if I'm diabetic?

The official labeling notes that the corticosteroid component can, in rare instances of systemic absorption, affect blood sugar levels, potentially leading to or worsening hyperglycemia. This effect may require consideration for patients with diabetes.

Q: Is there a risk of dependence or addiction with Oni?

Oni is not classified as a controlled substance by major regulatory bodies. Dependence or addiction is not listed as a risk in the official prescribing information for this topical combination.

Q: Does Oni require any special monitoring or regular blood tests?

Special monitoring is generally not required for short-term, correct use. Patients applying the cream to large surface areas or using it under occlusion (bandaging) may be periodically evaluated for signs of HPA-axis suppression, which can involve specific laboratory tests.

Q: Is Oni used in combination with other drugs sometimes?

Oni itself is a fixed combination of two active medicines. While it is not formally contraindicated for use alongside all other systemic medicines, the label specifically cautions against its use with other products containing corticosteroids.

Q: Does Oni interact with cold and flu medications?

The official prescribing information for topical Oni does not list specific interactions with common cold and flu medications. The main caution is regarding the co-administration of other corticosteroid products.

Q: Can people with high blood pressure use Oni safely?

The official labeling does not list high blood pressure as a formal contraindication. However, the corticosteroid component, if absorbed systemically from prolonged or excessive use, could potentially affect blood pressure.

Q: Why does the packaging for Oni recommend avoiding grapefruit?

The official prescribing information for topical Oni does not list a specific grapefruit interaction. Since Oni is applied topically, the metabolic concerns usually associated with consuming grapefruit with oral medicines are generally considered low.

Q: Is Oni available as a generic drug yet?

Yes, the combination of the active ingredients, Clotrimazole and Betamethasone Dipropionate, is widely available in a generic formulation.

Q: Is Oni a controlled substance?

No. According to major regulatory bodies, Oni (Clotrimazole and Betamethasone Dipropionate) is not classified as a controlled substance.

Q: Does Oni have a black box warning?

No. The official prescribing information for Oni (Clotrimazole and Betamethasone Dipropionate) does not contain a black box warning (formally called a Boxed Warning) from the FDA.

Q: Can Oni be cut in half or crushed?

Since Oni is a topical cream or ointment designed for external application to the skin, instructions for cutting or crushing (which typically applies to oral tablets) do not apply to this medication.

Q: What are the signs that Oni is actually working for me?

The primary clinical evidence of Oni working includes the reduction of inflammation (decreased redness and swelling) and the relief of symptoms like itching. Clearing of the fungal infection is expected to occur gradually as treatment continues.

Q: Does Oni affect mood or cause mood swings?

General mood changes or swings are not listed as common adverse effects for this topical medication. However, in rare instances of high systemic absorption, potent corticosteroids can have effects on the central nervous system.

How should Oni be stored and disposed of?

How to Store and Dispose of Oni? (Clotrimazole and Betamethasone Dipropionate Cream)

The official labeling mandates specific storage conditions to maintain product stability. Oni must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), with an allowed excursion up to 30 C. It is an explicit requirement to keep the product from freezing and to protect it from excessive heat, moisture, and light.

Handling and Disposal Requirements

Requirement Type Official Rule
Child Safety Keep out of the reach of children.
Container Rule Store in a closed container.
Disposal Dispose of unused or expired medicine in accordance with local requirements.

Regulatory instructions require that unused contents be discarded via an approved method, avoiding release to the general environment or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oni found in:

A-Z Index: